Summary of BioStem Technologies Conference Call Company Overview - **Company**: BioStem Technologies, Incorporated - **Acquisition**: BioTissue Holdings' surgical and wound care business - **Date of Announcement**: January 22, 2026 Key Points Industry and Market Expansion - The acquisition doubles BioStem's addressable market by entering the acute wound care market with leading skin substitute products and a robust commercial infrastructure [3][4] - The transaction is seen as a transformation of scale, capability, and market reach, aligning with long-term goals of diversifying end markets and expanding product portfolio [3][4] Financial Aspects - The acquisition cost includes an upfront cash payment of approximately $15 million, with potential additional payments of up to $10 million upon regulatory clearance and royalty payments of 7% of sales, capped at $15 million [12][54] - The acquired assets generated approximately $29 million in sales in 2025, expected to be growth and EBITDA accretive for BioStem in 2026 [13][45] Product Portfolio and Integration - BioStem's product portfolio will be expanded to include BioTissue's NEOX and Claryx product families, which are recognized in surgical and wound care [6][7] - The integration of BioTissue's products is expected to enhance BioStem's offerings in both chronic and acute wound care, particularly in hospital settings [4][6] Commercial Strategy - Barry Hassett has been appointed as Chief Commercial Officer to lead the next phase of growth, focusing on expanding the commercial footprint through BioTissue's experienced sales force [9][10] - The new sales team includes approximately 20 direct sales representatives and over 30 independent sales agents, aimed at establishing a presence in acute market settings [10][39] Operational Excellence - BioStem's vertically integrated manufacturing facility is expected to deliver industry-leading margins and high-quality performance, with plans to onboard acquired products to its facility after a 12-month transition period [11][12] - The company aims to achieve gross margin expansion as it transitions manufacturing in-house [11][54] Regulatory and Milestones - The BioTissue team submitted a 510(k) application for a flow-based product, with a milestone payment of $10 million contingent on its approval [42][43] - Key performance indicators (KPIs) for the acquisition will include revenue growth, market share expansion, and team growth [33][34] Market Dynamics - Changes in CMS reimbursement policies are expected to favor higher-quality products in hospital settings, allowing for a per-square-centimeter reimbursement structure [5][24] - The acquisition positions BioStem to leverage GPO contracts, enhancing access to major networks and strengthening its presence across various care settings [10][26] Conclusion - The acquisition is viewed as a strategic move to solidify BioStem's leadership in the wound care market, supporting a full continuum of wound healing from acute surgical repair to chronic wounds [14][57]

Core Viewpoint - BioStem Technologies, Inc. has commented on the withdrawal of all seven Local Coverage Determinations (LCDs) by the Centers for Medicare & Medicaid Services (CMS) for skin substitute grafts and cellular products for treating diabetic foot ulcers and venous leg ulcers, effective January 1, 2026, indicating that this will not impact patient access to their technology [1][2]. Company Overview - BioStem Technologies is a MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care [1]. - The company utilizes its proprietary BioRetain processing method, which is designed to maintain growth factors and preserve tissue structure [2]. - BioStem's quality management system has been accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [2]. Market and Innovation - The company emphasizes the importance of high-quality clinical evidence for long-term adoption and value creation, committing to an evidence-based strategy [2]. - BioStem plans to continue investing in expanding its clinical data foundation to demonstrate the differentiated performance of its proprietary technology compared to alternatives [2]. Product Portfolio - BioStem's product portfolio includes brands such as AmnioWrap2™, VENDAJE, and American Amnion™, all processed at their FDA registered and AATB accredited site in Pompano Beach, Florida [2].